ASP Isotopes Inc.

As of June 30, 2026, ASP Isotopes, Inc. carries a market capitalization of 1.39T, placing it among publicly traded companies globally. Its enterprise value stands at 1.43T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ASP Isotopes, Inc.'s next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, ASP Isotopes, Inc. has 130.15M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 22.55, and the price-to-book ratio stands at 3.21.

These figures are as of June 30, 2026. The EV/Sales ratio of 28.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.43T versus a market cap of 1.39T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ASP Isotopes, Inc. maintains a current ratio of 3.87, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 98.09, indicating elevated leverage, while an interest coverage ratio of -23.94 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, ASP Isotopes, Inc. posted a negative return on equity (ROE) of -91.09, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -37.30, reflecting losses generated across the asset base. The company generates approximately 213.00M in revenue per employee across its workforce of 237.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 19.59 indicates how many times ASP Isotopes, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ASP Isotopes, Inc. recorded 212.08M in income tax expense. The company reported a pretax loss of -224.06B and -216.28B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, ASP Isotopes, Inc.'s stock has declined approximately 79.26% over the past 52 weeks. The 50-day moving average sits at 5,296.72, while the 200-day moving average is 8,297.20.

Over the twelve months ended June 30, 2026, ASP Isotopes, Inc. generated 50.53B in revenue and converted that into -216.28B in net income, yielding earnings per share of -2,106.38. EBITDA reached -153.27B, while operating income came in at -157.82B.

As of June 30, 2026, ASP Isotopes, Inc. holds 417.50B in cash and equivalents against 441.49B in total debt, resulting in a net debt position of 71.29B. Total book value stands at 433.55B, with working capital of 330.67B providing operational flexibility.

ASP Isotopes, Inc. produced -111.06B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -25.83B in capital expenditures, free cash flow totaled -136.89B - equivalent to -1,285.71 per share.

Over the twelve months ended June 30, 2026, ASP Isotopes, Inc. posted a gross margin of 18.32, reflecting its pricing power and cost economics. The operating margin of -312.31 and net profit margin of -428.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -12.01: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -42.51, meaning ASP Isotopes, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, ASP Isotopes, Inc. has an Altman Z-Score of 0.96, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.